| 2023-FORT-69996 | |
| Researchers at Purdue University have developed a portfolio of small molecules that can reduce protein misfolding associated with the development of various diseases. A plethora of known diseases are classified as protein misfolding diseases with subsequent fibril formation. These diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, Type 2 diabetes, Lewy body dementia, and spongiform encephalopathy. There are currently limited general strategies that have emerged for developing small molecules capable of inhibiting the formation of fibrils, or to disaggregate amyloid deposits. Further, there are no effective therapies for resolving or halting neurodegenerative diseases associated with protein disorders. Researchers at Purdue University evaluated a set of 4-(2-benzothiazolyl) aniline (BTA) and its derivatives on their ability to modulate the folding of prone-to-aggregate proteins such as islet amyloid polypeptide (IAPP), amyloid-beta (A?1-40, A?1-42), transthyretin (TTR81-127, TTR101-125), ?-synuclein (?-syn), and tau isoform 2N4R (tau 2N4R). By utilizing various biophysical methods, researchers were able to study compounds and identify the compounds that held the most promise for treating protein misfolding disorders. This study provides an initial platform to generate more potent inhibitors of ?-syn, tau 2N4R, and TTR fibril formation in the future. Technology Validation: Transmission electron microscopy was used to confirm anti-fibrillary activity. The photoreactive cross-linking assay identified the most promising compound in reducing oligomerization. The most promising compound reduced the inclusions based on the cell-based assay using M17D neuroblastoma cells that express inclusion-prone ?S-3K::YFP. A Thioflavin-T fluorescence assay was used to monitor fibril formation after treatment with the BTA compounds and its derivatives. The most promising compound identified by this research abrogated the fibril, oligomer, and inclusion formation in a dose-dependent manner. Advantages: -Potent inhibition of fibril formation Applications: - Drug development - Drug discovery Related Publications: 5-Nitro-1,2-benzothiazol-3-amine and N-Ethyl-1- [(ethylcarbamoyl)(5-nitro-1,2-benzothiazol-3-yl)amino]formamide Modulate a-Synuclein and Tau Aggregation DOI: https://doi.org/10.1021/acsomega.3c02668?urlappend=%3Fref%3DPDF&jav=VoR&rel=cite-as |
|
|
|
|
Apr 24, 2023
Provisional-Gov. Funding
United States
(None)
(None)
Feb 3, 2023
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
